Medirom Healthcare Technologies Inc (MRM) Stock Analysis
Verdict: AVOID
A distressed balance sheet with a 0.24 current ratio makes this a high-risk play on a technical squeeze rather than fundamental value.
Investment score: 32/100
Analysis as of
Is Medirom Healthcare Technologies Inc stock worth reviewing? The TradeMates thesis
Medirom is a micro-cap with critical balance sheet flaws, specifically a current ratio far below 1.0 and persistent negative free cash flow. While the +34% 5-day move is eye-catching, it lacks fundamental support and appears to be a technical anomaly in a downward-trending stock.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Medirom Healthcare Technologies Inc opportunities and risks
What speaks for MRM
- Digital Pivot Upside
What speaks against MRM
- Immediate Liquidity Crisis
Peers and competitors
- 7074.T
- 6786.T
- 161A.T
- 1939.HK
- 308A.T
Frequently asked questions about Medirom Healthcare Technologies Inc (MRM)
Is MRM stock a good investment?
The TradeMates model rates Medirom Healthcare Technologies Inc as AVOID with an investment score of 32/100. Medirom is a micro-cap with critical balance sheet flaws, specifically a current ratio far below 1.0 and persistent negative free cash flow. While the +34% 5-day move is eye-catching, it lacks fundamental support and appears to be a technical anomaly in a downward-trending stock. This is algorithmic model output, not personal investment advice.
Is MRM stock a buy?
The TradeMates model verdict for MRM is AVOID with an investment score of 32/100. Treat this as a model signal to review, not a personal buy recommendation.